Silver Book Fact

A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.

Parkinson Study Group. A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. Arch Neurol. 2005; 62(2): 241-8. http://archneur.ama-assn.org/cgi/content/full/62/2/241

Reference

Title
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Publication
Arch Neurol
Publication Date
2005
Authors
Parkinson Study Group
Volume & Issue
Volume 62, Issue 2
Pages
241-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicaid costs for people with the disease would be…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years were introduced in 2015, by 2050 the total reduction in cost of care for people…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…  
  • The U.S. Food and Drug Administration has approved 5 drugs for the treatment of Alzheimer’s disease. These drugs have been found to temporarily slow the worsening of Alzheimer’s symptoms for…